Researchers in December launched a new randomized trial for elderly patients with intermediate-grade nonHodgkin 's lymphoma (NHL) to test a novel alternative to CHOP ( cyclophosphamide, vincristine, doxorubicin, and prednisone), the standard chemotherapy for this form ofNHL. The phase III trial will compare CHOP alone to CHOP plus the new monoclonal antibody, IDEC-C2B8 (Rituxan®).
The trial stands out on one hand for its new approach to intermediate-grade NHL; Rituxan's recent Food and Drug Administration approval was for lowgrade NHL. But it may be even more notable for its specific focus on older patients and the need to find alternatives to CHOP in this age group. 
Cures Only Half
Demographics are not the only reason researchers are focusing more on NHL in older people. Another impetus is the fact that treatment for intermediategrade lymphoma-common among elderly NHL patients -is markedly less successful in older patients. CHOP cures only about half as many elderly patients as younger patients, according to Connors and O'Reilly. And a recent international study of prognostic indicators in NHL found that age -being over age 60 -was the most important factor independently associated with poorer survival in patients with intermediate-and high-grade lymphoma.
"We know from this prognostic index that we should be looking for an alternative for patients age 60 and above," said Habermann.
One alternative could be CHOP plus the monoclonal antibody. The new trial, organized by the Eastern Cooperative Oncology Group (ECOG), will recruit 630 patients age 60 and over, and randomly assign them to receive either CHOP alone or CHOP with Rituxan, which targets the B-cell protein CD20.
Another possible improvement on CHOP in the elderly is the addition of maintenance therapy, and the new ECOG trial will also test this possibility. After initial therapy, patients who responded will be again randomly assigned to receive the maintenance regimen -Rituxan every 6 months for 2 years -or observation. This is the first randomized trial to address maintenance therapy of any kind in NHL, Habermann said.
CHOP alternatives could also turn out be less toxic chemotherapy regi- Another recent, multicenter trial by a cooperative group in France found that CTVP (cyclophosphamide, tenoposide, prednisone, and pirarubicin) did better than the same combination minus pirarubicin, which is an anthracycline similar to doxorubicin, in patients older than 69 years of age. Because CTVP is quite similar to CHOP, this finding provides more support for the use of the stronger, antracyclin-based regimens.
Less Toxic Options
Meanwhile, the search for other drug combinations that may be as effective but less toxic than CHOP continues. At Aviano, for instance, investigators led by Vittorina Zagonei, M.D., have launched a trial comparing CHOP to CIEP, in which the less toxic idarubicin and VP16(P) are substituted for CHOP's doxorubicin and vincristine.
Still another strategy is the use of fewer doses of CHOP in elderly patients who cannot tolerate the full regimen. O'Reilly said that Vancouver scientists have a phase II study in progress looking at a four-treatment "mini-CHOP," called COPA, in elderly patients. COPA uses the same drugs as CHOP given in reduced doses along with supportive agents, such as an antibiotic and an antifungal. Preliminary data, O'Reilly said, suggest that outcomes are similar to CHOP in the elderly with less chance of side effects.
One more approach to NHL in the elderly involves peripheral stem cell transplants an approach that is combined with low-dose chemotherapy tegimens," according to Julie Vose, M.D., at the University ofNebraska. The idea is that stem cells from a sibling donor may induce a graft vs. tumor effect, i.e., the siblng stem cells will mount an immune response against the host cancer cells. In these studies and others focusing on the elderly, data on length of diseasefree and overall survival will be key. Often elderly people respond to therapy initially but do not maintain remissions as long as younger people. "The elderly have a higher relapse rate;' said Vose, "and we don't really understand why. So we're always looking for something better."
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